BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37294386)

  • 1. Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-institutional Analysis.
    SenthilKumar G; Kothari AN; Maduekwe UN; Fournier K; Abbott DE; Wilson GC; Patel SH; Greer J; Johnston F; Dineen SP; Powers BD; Baumgartner J; Veerapong J; Leiting J; Grotz TE; Maithel SK; Staley C; Raoof M; Lambert L; Lee A; Kim A; Cloyd JM; Mogal H
    Ann Surg Oncol; 2023 Sep; 30(9):5743-5753. PubMed ID: 37294386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms.
    Erstad DJ; Robinson KA; Beaty K; Rafeeq S; Chiang YJ; Raghav K; Shen JP; Overman MJ; Foo WC; Taggart MW; Mansfield PF; Royal RE; Fournier KF; Scally CP
    Langenbecks Arch Surg; 2023 Feb; 408(1):110. PubMed ID: 36853519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease?
    Beal EW; Chen JC; Kim A; Johnston FM; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Clarke C; Staley C; Patel SH; Lambert L; Cloyd JM
    J Surg Res; 2022 Sep; 277():269-278. PubMed ID: 35525209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
    Wagner PL; Austin F; Zenati M; Jaech A; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 May; 23(5):1587-93. PubMed ID: 26744106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
    Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
    Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Baron E; Sardi A; King MC; Nikiforchin A; Lopez-Ramirez F; Nieroda C; Gushchin V; Ledakis P
    Eur J Surg Oncol; 2023 Jan; 49(1):179-187. PubMed ID: 36253240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 Feb; 23(2):382-90. PubMed ID: 26429720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
    Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
    Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms.
    Valenzuela CD; Mangieri CW; Garland-Kledzik M; Gawdi R; Russell G; Perry KC; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3422-3431. PubMed ID: 35254575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Survival Outcomes and Impact of EPIC in Patients Undergoing CRS/HIPEC for Mucinous Appendiceal Neoplasm.
    Mercado M; Shamavonian R; Cheng E; Ahmadi N; Morris DL
    Anticancer Res; 2023 Feb; 43(2):817-822. PubMed ID: 36697077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative.
    Beal EW; Srinivas S; Shen C; Kim A; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Grotz TE; Leiting JL; Fournier K; Dineen S; Powers B; Veerapong J; Kothari A; Maduekew U; Maithel S; Wilson GC; Patel SH; Lambert L; Abdel-Misih S; Cloyd JM
    Ann Surg Oncol; 2023 Mar; 30(3):1840-1849. PubMed ID: 36310315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.